PO-0974: Urethral and bladder dose of total and focal salvage brachytherapy: toxicity and dose constraints  by Peters, M. et al.
S474                                                                                                                                                    ESTRO 35 2016 
______________________________________________________________________________________________________ 
autoradiograph. (c) The subtracted image clearly showing the 
physical position of the source in the applicator and path of 
the drive cable through the applicator lumen. 
 
Conclusion: We have demonstrated a filmless approach to 
determining actual source positions corresponding to each 
dwell position in each channel of two gynaecological HDR 
brachytherapy applicators. Accuracy is generally sub-
millimetre and can also be used to quantify the accuracy of 
using marker-wire defined positions for reconstructing 
applicators in planning. The flat panel detector method is 
efficient and provides additional information not possible 
with radiochromic film. 
 
Poster: Brachytherapy track: Prostate  
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Purpose or Objective: Salvage Iodine-125 brachytherapy (I-
125-BT) constitutes a curative treatment approach for 
patients with organ-confined recurrent prostate cancer after 
primary radiotherapy. Currently, focal salvage (FS) instead of 
whole-gland or total salvage (TS) is being investigated, to 
reduce severe toxicity associated with cumulative radiation 
dose. Differences in urethral and bladder dosimetry and 
constraints to reduce late (>90 days) genitourinary (GU) 
toxicity are presented here. 
 
Material and Methods: Dosimetry on intraoperative 
ultrasound (US) of 20 FS and 28 TS patients was compared. 
The prostate, bladder, urethra (figure 1) and 
bulbomembranous (BM) urethra were delineated. Toxicity 
was assessed using the CTCAE version 4.0. Dose constraints to 
reduce toxicity in TS patients were evaluated with receiver 
operating characteristic (ROC) analysis. 
 
 
 
Figure. 1. Urethral (= yellow) D10 difference for TS (A) 
compared FS (B). The urethral D10 in A was 270 Gy versus 100 
Gy in B. 
 
Results: FS I-125 BT significantly reduces bladder and 
urethral dose compared to TS. Grade 3 GU toxicity occurred 
once in the FS group. For TS patients late severe (≥grade 3) 
GU toxicity was frequent (38% in the total 61 patients and 
56% in the 27 analyzed patients). TS patients with ≥grade 3 
GU toxicity showed higher bladder D2cc than TS patients 
without toxicity (median 43 Gy) (p = 0.02). The urethral V100 
was significantly higher in TS patients with several toxicity 
profiles:≥grade 3 urethral strictures,≥grade 2 urinary 
retention and multiple ≥grade 2 GU toxicity events. Dose to 
the BM urethra did not show a relation with stricture 
formation. ROC-analysis indicated a bladder D2cc <70 Gy to 
prevent ≥grade 3 GU toxicity (AUC 0.76, 95%CI: 0.56–0.96, p = 
0.02). A urethral V100 <0.40 cc (AUC from 0.73–0.91, p = 
0.003–0.05) could prevent other late GU toxicity. 
 
Conclusion: FS I-125 BT reduces urethral and bladder dose 
significantly compared to TS. With TS, there is an increased 
risk of cumulative dose and severe GU toxicity. Based on 
these findings, bladder D2cc should be below 70 Gy and 
urethral V100 below 0.40 cc. 
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Purpose or Objective: To report 5 and 8-year clinical 
outcomes, early and late complications in 226 patients with 
prostate cancer treated with high-dose-rate brachytherapy 
(HDR-BT) in combination with external-beam radiotherapy 
(EBRT). 
 
Material and Methods: Between 2004 and 2010, 226 patients 
underwent HDR-BT in combination with EBRT as a treatment 
for their low, intermediate or high risk prostate cancer. The 
HDR-BT procedure was performed using ultrasound-based 
transperineal implantation. The total HDR-BT dose was 16 - 
18Gy in 2. The EBRT technique used by treatment was 3D-
CRT (70.3%) or IGRT/IMRT (29.7%) with daily correction of set 
up errors. Total dose of EBRT for low risk patients was 45Gy 
in 25 fractions of 1.8Gy within 5 weeks. For intermediate and 
high-risk patients the dose was 50.4Gy in 28 of 1.8Gy within 5 
weeks. Patients were stratified by risk factors in to risk 
groups – 67 (29.5%) low, 87 (38.5%) intermediate and 72 
(32.0%) high risk patients. Neoadjuvant hormonal therapy was 
applied in patient of intermediate or high risk of recurrence. 
High risk patients recieved adjuvant hormonal therapy.  
 
Results: 5-year results after a mean follow-up of 70 months 
of the 226 patients the freedom from biochemical failure was 
92.5%. 17 patients (7.5%) showed prostate specific antigen 
progression according to the Phoenix definition. In 9 patients 
clinical progression (bone or lymph node metastases) was 
documented. 8-year results after a mean follow up of 96 
months of the 130 patients the freedom from biochemical 
failure was 82%. 23 patients (18.0%) showed prostate specific 
antigen progression. In 11 patients clinical progression was 
documented. Cancer specific survival during 5-year and 8-
year follow up was 99.1% and 96.8% respectively. Toxicity 
was scored using the EORTC/RTOG score system. During 
follow up we haven´t observed any consequential toxicity or 
relationship between acute and late toxicity respectively. 
Higher incidence of GU and GIT toxicity was observed in 
patients treated by 3D-CRT technique. Acute and late 
gastrointestinal toxicity (GIT) was very low. Toxicity grade 2 
was observed in 1.3% No grade 3 or 4 GIT toxicity was 
observed. Acute GU toxicity in most cases was grade 1 
(40.2%) or grade 2 (10.6%). Late GU toxicity was also in most 
cases grade 1 (32.7%) or grade 2 (10.1%). Grade 3 toxicity was 
observed only in 2.2%. Grade 4 toxicity didn´t occurred. We 
have detected a trend that higher grade late GU toxicity was 
observed after longer period of treatment than lower grade. 
Mean time of occurrence for grade 3 and 2 was 64 and 23 
months respectively, compared to mean time 12 months for 
grade 1. 
 
Conclusion: Combination of external beam radiotherapy with 
high-dose-rate interstitial brachytherapy boost is safety and 
effective option in treatment localized prostate cancer. Our 
results show a low incidence of acute and late complications 
with favorable oncologic outcome after 5 and 8 year follow 
up.  
 
 
 
 
